These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27717419)

  • 21. Loss of tolerance to one or two major targets in Crohn's disease or just cross-reactivity?
    Roggenbuck D; Bogdanos D; Conrad K
    J Crohns Colitis; 2013 Aug; 7(7):e273-4. PubMed ID: 23337370
    [No Abstract]   [Full Text] [Related]  

  • 22. The Intestinal Microbiota in Inflammatory Bowel Disease.
    Becker C; Neurath MF; Wirtz S
    ILAR J; 2015; 56(2):192-204. PubMed ID: 26323629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses.
    Werner L; Paclik D; Fritz C; Reinhold D; Roggenbuck D; Sturm A
    J Immunol; 2012 Sep; 189(6):2774-83. PubMed ID: 22891285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The genetics of Crohn's disease and ulcerative colitis--status quo and beyond.
    Ellinghaus D; Bethune J; Petersen BS; Franke A
    Scand J Gastroenterol; 2015 Jan; 50(1):13-23. PubMed ID: 25523552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmunity, inflammatory bowel disease and hyposplenism.
    Ryan FP; Ward AM; Holdsworth CD
    Q J Med; 1991 Jan; 78(285):59-63. PubMed ID: 1670065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.
    Sowa M; Kolenda R; Baumgart DC; Pratschke J; Papp M; Tornai T; Suchanski J; Bogdanos DP; Mytilinaiou MG; Hammermann J; Laass MW; Conrad K; Schramm C; Franke A; Roggenbuck D; Schierack P
    Front Immunol; 2018; 9():1959. PubMed ID: 30233574
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.
    Kohoutova D; Drahosova M; Moravkova P; Rejchrt S; Bures J
    BMC Gastroenterol; 2014 Dec; 14():190. PubMed ID: 25551469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and validation of murine monoclonal and camelid recombinant single domain antibodies specific for human pancreatic glycoprotein 2.
    Schlör A; Holzlöhner P; Listek M; Grieß C; Butze M; Micheel B; Hentschel C; Sowa M; Roggenbuck D; Schierack P; Füner J; Schliebs E; Goihl A; Reinhold D; Hanack K
    N Biotechnol; 2018 Oct; 45():60-68. PubMed ID: 29635104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
    Bonneau J; Dumestre-Perard C; Rinaudo-Gaujous M; Genin C; Sparrow M; Roblin X; Paul S
    Autoimmun Rev; 2015 Mar; 14(3):231-45. PubMed ID: 25462578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of antibiotics for treatment of inflammatory bowel disease.
    Nitzan O; Elias M; Peretz A; Saliba W
    World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity?
    Marks DJ
    Curr Opin Gastroenterol; 2011 Jul; 27(4):328-34. PubMed ID: 21483259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contentious host-microbiota relationship in inflammatory bowel disease--can foes become friends again?
    Satokari R
    Scand J Gastroenterol; 2015 Jan; 50(1):34-42. PubMed ID: 25523554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders.
    Papa Gobbi R; De Francesco N; Bondar C; Muglia C; Chirdo F; Rumbo M; Rocca A; Toscano MA; Sambuelli A; Rabinovich GA; Docena GH
    Biofactors; 2016; 42(1):93-105. PubMed ID: 26891020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
    Strober W; Asano N; Fuss I; Kitani A; Watanabe T
    Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insight into Crohn's disease pathomorphology.
    Mudter J; Neurath MF
    Abdom Imaging; 2012 Dec; 37(6):921-6. PubMed ID: 22476334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intestinal flora and Crohn's disease].
    Desreumaux P; Colombel JF
    Ann Pharm Fr; 2003 Jul; 61(4):276-81. PubMed ID: 12843962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
    Merga Y; Campbell BJ; Rhodes JM
    Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.